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Previewsof nonribosomal peptides. The strategies
described by Liu et al. (2011) and Sundlov
et al. (2012) promise to lead to a better
understanding of the workings of these
complex and fascinating molecular
machines and serve as a first step in the
development of tailor-made NRPSs.
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Targeting a specific arm of signaling pathways is of great interest. In this issue ofChemistry & Biology, Bosco
et al. exploit the interactive interface between Rac GTPase and its effector p67phox to specifically inhibit reac-
tive oxygen species production without perturbing other Rac-mediated cellular processes.The coordinated assembly of multiprotein
complexes is essential for the transmission
of multiple downstream signaling path-
ways. Chemical tools that interfere with
the assembly of such complexes are highly
desirable to tease out the intracellular
signaling networks. Upon stimulation,
NADPH oxidase, a key cellular enzyme
responsible for generating the reactive
oxygen species (ROS), is assembled into
an active complex at the membrane. ROS
is the central weapon of phagocytes to
combat the invading microorganisms. It
also plays important regulatory functions
during neutrophil chemotaxis (Hattori
et al., 2010). Inefficient generation of ROS
due to genetic mutations of the compo-
nents of NADPH oxidase leads to chronic
granulomatous disease, which is typically
characterized by the inability to fight infec-
tion and aberrant inflammation. Beyond
their well-characterized traditionally roles
in innate immunity and inflammation,
more recently, ROS and NADPH oxidase
are actively being scrutinized as the key
mediators of a multitude of pathologicalconditions caused by oxidative stresses,
including neurological diseases, cardio-
vascular pathologies, and cancer (Bedard
and Krause, 2007; Kleinschnitz et al.,
2010; Williams and Griendling, 2007).
Accordingly, specific pharmacological
inhibitors of ROS production by NADPH
oxidase are being sought after for the ther-
apeutic benefits of various human patholo-
gies contributed by the oxidative stresses.
Targeting the assembly of active
NADPH oxidase complex is an efficient
way to inhibit ROS production. The
central components of active NADPH
oxidase consist of two membrane-bound
subunits, gp91phox (or Nox2) and p22phox,
four cytosolic proteins, p47phox, p67phox,
p40phox, and small GTPase Rac. In
response to external stimuli, the cytosolic
components are translocated to the
membrane and interact with the mem-
brane-bound components to assemble
an active NADPH complex, which then
transfer electrons from NADPH to oxygen
to generate the reactive superoxide anion
(Figure 1). A series of protein-proteininteractions are critical for an efficient
assembly of fully active NADPH oxidase
complex. For example, the C-terminal
part of cytosolic subunit p67phox interacts
with p47phox, while the N-terminal half of
p67phox is capable of binding to Rac.
The GTP-bound activated Rac recruits
p67phox to the membrane, hence facili-
tating the assembly of NADPH oxidase
complex and its activation. As demon-
strated by a small molecule inhibitor
(Gao et al., 2004), targeting Rac activity
is a legitimate strategy to interfere with
the assembly of NADPH complex and
ROS production. However, given the
pleiotropic regulatory functions of Rac in
a wide range of cellular functions, the
‘‘global’’ inhibition of Rac activity inevi-
tably comes with the risk of unintended
side effects, concomitant with inhibition
of ROS generation. On the other hand, the
‘‘pathway-selective’’ inhibition of down-
stream of Rac signaling may specifically
abrogateROSproductionwithout affecting
other Rac-dependent cellular processes.
Because the specific interactions betweenª2012 Elsevier Ltd All rights reserved 169
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Figure 1. Assembly of NADPH Oxidase Complex and Its Inhibition by Phox-I
(A) In resting state, the membrane-bound and cytosolic components of NADPH oxidase are segregated. The inactive GDP-bound Rac GTPase also resides in the
cytoplasm, in association with Rho-GDP dissociation inhibitor (GDI).
(B) Upon stimulation, the cytosolic components are translocated to the membrane and interact with the membrane-bound components to assemble an active
NADPH complex, which then transfer electrons from NADPH to oxygen to generate the reactive superoxide anion. The GTP-bound activated Rac recruits
p67phox to the membrane, hence facilitating the assembly of NADPH oxidase complex and its activation. The active Rac also interact with other effectors to
mediate downstream cellular responses such as the organization of cytoskeleton.
(C) A small molecule Phox-I disrupts the interaction between Rac and p67phox effector and specifically inhibits ROS production without affecting other Rac-
mediated pathways.
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PreviewsRac and its effectors dictate consequent
downstream cellular responses, chemi-
cally exploiting such interactive interfaces
may pave the way for the ‘‘pathway-selec-
tive’’ inhibition.
In this issue ofChemistry & Biology, Bo-
sco et al. (2012) present a novel strategy
to rationally design small molecules that
target the interactive interface between
Rac and its effector p67phox, which allows
for the specific inhibition of ROS produc-
tion by NADPH oxidase complex. To
embark on this task, the authors first
took full advantage of previous structural
and mutagenesis studies that identified
a binding pocket within p67phox critical
for interaction with the active Rac
(Lapouge et al., 2000). This structural
information enabled the structure-based
virtual screening of small molecules that
might target this binding interface and
disrupt the formation of p67phox complex
with Rac. From the initial screening of
over 700,000 compounds followed by
several rounds of molecular docking and
data refinement, the top 9 candidates pre-
dicted to be specific to p67phox were
selected. A representative compound
Phox-I1 was experimentally tested for its
binding to p67phox and ability to disrupt
the p67phox interaction with Rac. To this
end, they employed the microscale
thermophoresis, which measures the
changes in fluorescent intensity upon
protein-protein or protein-small molecule
interactions in near-native conditions.
Using the purified wild-type and mutant
proteins of both p67phox and Rac, they170 Chemistry & Biology 19, February 24, 201demonstrated the specificity of Phox-I1
in disrupting the interaction between
p67phox and GTP-bound active Rac.
Next, to determine if Phox-I1 could
inhibit ROS production, they employed
cell-based functional assays using the
fMLP-induced NADPH oxidase activation
in different cell types, including primary
murine and human neutrophils. In these
assays, Phox-I1manifested a comparable
or better potency in comparison to other
known compounds such as ROS scav-
enger, pan-inhibitor of NADPH oxidase,
and Rac-GTP inhibitor. Phox-I1 had no
inhibitory effect toward either the PMA-
induced ROS production in cells or the
glucose oxidase-mediated ROS genera-
tion in vitro. Having validated the utility of
Phox-I1 in specifically abrogating fMLP-
induced ROS production, they went on
to carry out the structure-activity relation-
ship (SAR) studies to indentify the neces-
sary chemical moiety and to improve the
potency. A substructure search of data-
base identified a series of compounds,
which they grouped into two categories:
‘‘Phox-I1-like’’ and ‘‘Phox-I2-like’’. Like
Phox-I1, a second generation lead
compound, Phox-I2, displayed a specific
inhibitory activity toward ROS production.
More importantly, unlike the general inhib-
itors of Rac activity (Ferri et al., 2009; Gao
et al., 2004), in the presence of Phox-I1
and Phox-I2, the active Rac-mediated
F-actin assembly upon fMLP stimulation
was unaffected, highlighting their
‘‘pathway-selective’’ inhibition of p67phox
effector arm of Rac signaling. Further,2 ª2012 Elsevier Ltd All rights reservedSAR studies of chemical scaffold of
Phox-I1 and Phox-I2 will lead to the devel-
opment of promising ROS inhibitors with
a higher specificity for the clinical utility.
In conclusion, the current body of
work by Bosco et al. (2012) clearly repre-
sents a proof of principle for the novel
concept of exploiting chemical biology
approaches to tease out cellular functions
of pleiotropic regulators, such as Rac
GTPase. Unlike the activity-based high
throughput screening, the execution of
virtual screening requires the preexisting
detailed understanding of specific molec-
ular interactions. However, with the
exponentially growing number of small
molecules and computational capacity
combined with the protein-protein interac-
tion networks, the rational design of small
molecules with exquisite properties to tell
apart the complicated cellular circuits
may become attainable in the future.
Finally, as implicated by this study (Bosco
et al., 2012), harnessing the power of virtual
screening may become a standard prac-
tice that enables the activity-based high
throughput screening more efficient.REFERENCES
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